These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 19640184)

  • 1. Toward prostate cancer early detection in Iran.
    Mousavi SM
    Asian Pac J Cancer Prev; 2009; 10(3):413-8. PubMed ID: 19640184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gastric cancer in Iran 1966-2006.
    Mousavi SM; Somi MH
    Asian Pac J Cancer Prev; 2009; 10(3):407-12. PubMed ID: 19640183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate Cancer in Iran: Trends in Incidence and Morphological and Epidemiological Characteristics.
    Pakzad R; Rafiemanesh H; Ghoncheh M; Sarmad A; Salehiniya H; Hosseini S; Sepehri Z; Afshari-Moghadam A
    Asian Pac J Cancer Prev; 2016; 17(2):839-43. PubMed ID: 26925689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer surveillance using registry data: Results and recommendations for the Lithuanian national prostate cancer early detection programme.
    Gondos A; Krilaviciute A; Smailyte G; Ulys A; Brenner H
    Eur J Cancer; 2015 Aug; 51(12):1630-7. PubMed ID: 26044924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Age-Adjusted PSA Levels in Prostate Cancer Prediction: Updated Results of the Tyrol Prostate Cancer Early Detection Program.
    Heidegger I; Fritz J; Klocker H; Pichler R; Bektic J; Horninger W
    PLoS One; 2015; 10(7):e0134134. PubMed ID: 26218594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Adenocarcinoma of the prostate].
    Dvorácek J
    Cas Lek Cesk; 1998 Aug; 137(17):515-21. PubMed ID: 9787503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Should prostate-specific antigen screening be offered to asymptomatic men?
    van Vugt HA; Bangma CH; Roobol MJ
    Expert Rev Anticancer Ther; 2010 Jul; 10(7):1043-53. PubMed ID: 20645694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of prostate cancer diagnosis in the eras before and after serum prostate-specific antigen testing.
    Jacobsen SJ; Katusic SK; Bergstralh EJ; Oesterling JE; Ohrt D; Klee GG; Chute CG; Lieber MM
    JAMA; 1995 Nov; 274(18):1445-9. PubMed ID: 7474190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate cancer trends in Canada: rising incidence or increased detection?
    Levy IG; Gibbons L; Collins JP; Perkins DG; Mao Y
    CMAJ; 1993 Sep; 149(5):617-24. PubMed ID: 8364818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
    Hammarsten J; Högstedt B
    Scand J Urol Nephrol; 2002; 36(5):330-8. PubMed ID: 12487736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The incidence of prostate cancer in Iran: results of a population-based cancer registry.
    Sadjadi A; Nooraie M; Ghorbani A; Alimohammadian M; Zahedi MJ; Darvish-Moghadam S; Fakheri H; Babai M; Semnani S; Mansour-Ghanaei F; Mohagheghi MA
    Arch Iran Med; 2007 Oct; 10(4):481-5. PubMed ID: 17903053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Should baseline PSA testing be performed in men aged 40 to detect those aged 50 or less who are at risk of aggressive prostate cancer?
    Heyns CF; Fisher M; Lecuona A; Van der Merwe A
    S Afr Med J; 2011 Sep; 101(9):642-4. PubMed ID: 21920156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Epidemiological fundamentals of clinically localized prostate cancer].
    Martínez-Salamanca JI; Ballesteros CM; Carballido Rodríguez J
    Arch Esp Urol; 2011 Oct; 64(8):703-10. PubMed ID: 22052753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in case mix and treatment patterns in prostate cancer in Saskatchewan during the prostate specific antigen testing era.
    Tonita JM; Skarsgard D; Muhajarine N
    Cancer Causes Control; 2009 Mar; 20(2):201-9. PubMed ID: 18825504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam).
    Roobol MJ; Roobol DW; Schröder FH
    Urology; 2005 Feb; 65(2):343-6. PubMed ID: 15708050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serial prostate specific antigen, free-to-total prostate specific antigen ratio and complexed prostate specific antigen for the diagnosis of prostate cancer.
    Ellis WJ; Etzioni R; Vessella RL; Hu C; Goodman GE
    J Urol; 2001 Jul; 166(1):93-8; discussion 98-9. PubMed ID: 11435831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Diagnosis based on prostate needle biopsy: inadequate correlation between pathologic results and clinical course for individual prognosis].
    van der Kwast TH; Hoedemaeker RF; Schröder FH
    Ned Tijdschr Geneeskd; 2005 Apr; 149(18):972-6. PubMed ID: 15903037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence and pathological characteristics of prostate cancer in Italy: a contribution to the screening debate.
    Picone GM; Pizzi C; Quartuccio A; Scognamiglio G; Tauchmanova L; Di Maio M; Cifarelli P; Contegiacomo A
    Cancer Detect Prev; 2006; 30(5):455-8. PubMed ID: 17067751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trends in prostate needle biopsy diagnosis. A ten year experience of a medical center in Taiwan.
    Kuo YJ; Lin SF; Chang YH; Pan CC
    Pathol Int; 2012 Mar; 62(3):191-8. PubMed ID: 22360507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of prostate cancer: the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
    Schröder FH
    Can J Urol; 2005 Feb; 12 Suppl 1():2-6; discussion 92-3. PubMed ID: 15780157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.